Anemia in Chronic Kidney Disease (Ckd). Do we know how to Treat it Properly?
DOI:
https://doi.org/10.12775/mbs-2013-0004Keywords
renal anemia, chronic kidney disease, iron, hemoglobin, erythropoietinAbstract
Renal anemia is one of the major complications observed in patients with chronic kidney disease (CKD). It is caused mainly by a relative erythropoietin deficiency due to progressive damage of renal parenchyma. The primary goal of anemia treatment using available today ESAs is not only to improve the quality of life of patients but, above all to reduce cardiovascular mortality. The target hemoglobin concentration during application of ESA in CKD patients treated conservatively and renal replacement therapy patients was and still is being discussed among nephrologists. Based on the clinical trials performed so far, it seems that in patients with renal anemia we should individualise treatment with ESA, seeking partial rather than complete correction of anemia.References
Jurkovitz CT, Abramson JL, Vaccarino LV et al.: “Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study.” J Am Soc Nephrol 2003; 14:2919-2925[http://dx.doi.org/10.1097/01.ASN.0000092138.65211.71]
Pisoni RL, Bragg-Gresham JL, Young EW et al.:”Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS)”. Am J Kidney Dis 2004;44:94-111
KDOQI Clinical Practice Guadelines and Clinical Practice Recommendations for Anemia In Chronic Kidney Disease. Am J Kidney Dis 2006; 47:S11-145
Samouilidou EC, Grapsa EJ, Kakavas I et al.:” Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis”. Int. Urol. Nephrol., 2007; 39: 1323-1324[http://dx.doi.org/10.1007/s11255-007-9248-0]
Dirican M, Sarandol E, Serdar Z et al.:”Oxidative status and prevalent cardiovascular disease in patients with chronic renal failure treated by hemodialysis”. Clin Nephrol. 2007;68:144-150[http://dx.doi.org/10.5414/CNP68144]
Kuusniemi AM, Lapatto R, Holmberg C et al.:” Kidneys with heavy proteinuria show fibrosis, inflammation, and oxidative stress, but no tubular phenotypic change”. Kidney Int., 2005, 68, 121-132
Marathias KP, Agroyannis B, Mavromoustakos T et al.:” Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers”. Curr Top Med. Chem 2004;4:483-486 [http://dx.doi.org/10.2174/1568026043451311]
Slagman C.J. Martje, Sinkeler Steef J. et al.: Erythropoetin is reduced by combination of diuretic theraphy and RAAS blockade in proteinuric renal patients with preserved renal function. Nephrol Dial Transplant 2010; 25: 3256-3260
Macdougall IC. : Iron supplementation in the nondialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr. Med. Res. Opin. 2010 Feb;26(2):473-82[http://dx.doi.org/10.1185/03007990903512461]
Levin A:”Anemia and left ventricular hypertrophy In chronic kidney disease populations: A review of the current state of knowledge”. Kidney Int. Suppl. 2002; 80:35-38 [http://dx.doi.org/10.1046/j.1523-1755.61.s80.7.x]
Drueke TB, Locatelli F, Clyne N et al.:”Normalization of hemoglobin level in patients with chronic Sidney disease and anemia”. N. Engl. J. Med. 2006; 355:2071-2084
Singh A., Szczech L, Tang KL et al.:”Correction of anemia with epoetin alfa in chronic kidney disease”. N. Engl. J. Med. 2006;355:2085-2098
KDOQI clinical practice guadeline and clinical practice recomendations for anemia in chronic kidney disease, 2007 update of hemoglobin target. Am J. Kidney Dis 2007; 50:471-530
Takahashi K, Totsune K, Imai Y et al.:“Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin” Clin Sci 1993;84:47-50
Bittorf T, Büchse T, Sasse T et al.:"Activation of the transcription factor NF-kappa B by the erythropoietin receptor: structural requirements and biological significance”. Cell Signal 2001;13:673-681[http://dx.doi.org/10.1016/S0898-6568(01)00189-9]
Pfeffer MA, Pfeffer MA, Burdmann EA et al.:”A trial of darbopoetin alfa in type 2 diabetes and chronic kidney disease”. N Eng J Med 2009; 361: 2019-2032.
Więcek A: “To TREAT or not to TREAT-that is the question” Nat Rev Nephrol. 2010;6:254-255[http://dx.doi.org/10.1038/nrneph.2010.35]
Agarwal R, Vasavada N, Sachs NG et al.: ”Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease” Kidney Int. 2004; 65:2279-2289 [http://dx.doi.org/10.1111/j.1523-1755.2004.00648.x]
Kapoian T, O'Mara NB, Singh AK et al.: ”Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.” J Am. Soc. Nephrol. 2008; 19: 372-379 [http://dx.doi.org/10.1681/ASN.2007050606]
Silverberg DS.: The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome Heart Fail Rev. 2011 Nov;16(6):609-14. [http://dx.doi.org/10.1007/s10741-010-9194-2]
Xia H, Ebben J, Ma JZ et al. :”Hematocrit levels and hospitalization risks in hemodialysis patients.” J Am Soc Nephrol. 1999;10:1309-1316
Besarab A, Bolton WK, Browne JK et al.:” The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590
Vaziri D, Xin J. Zhou: "Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease". Nephrol Dial Transplant 2009; 24:1082-1088
Downloads
Published
How to Cite
Issue
Section
Stats
Number of views and downloads: 366
Number of citations: 0
